Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$248.060.0%$226.15$184.63▼$261.64$438.31B0.39.03 million shs4.14 million shsVRTXVertex Pharmaceuticals$480.25-1.1%$458.18$362.50▼$533.67$123.19B0.291.96 million shs1.15 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.02%-2.63%+9.02%+17.96%+28.98%VRTXVertex Pharmaceuticals-1.06%-9.32%+7.94%+8.10%+2.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$248.060.0%$226.15$184.63▼$261.64$438.31B0.39.03 million shs4.14 million shsVRTXVertex Pharmaceuticals$480.25-1.1%$458.18$362.50▼$533.67$123.19B0.291.96 million shs1.15 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.02%-2.63%+9.02%+17.96%+28.98%VRTXVertex Pharmaceuticals-1.06%-9.32%+7.94%+8.10%+2.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$266.247.33% UpsideVRTXVertex Pharmaceuticals 2.84Moderate Buy$559.6116.52% UpsideCurrent Analyst Ratings BreakdownLatest VRTX and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026VRTXVertex Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$545.00 ➝ $585.007/13/2026ABBVAbbVie UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$230.00 ➝ $260.007/13/2026VRTXVertex Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$542.00 ➝ $560.007/13/2026ABBVAbbVie BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$258.00 ➝ $300.007/10/2026ABBVAbbVie Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $295.007/10/2026ABBVAbbVie Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$234.00 ➝ $276.007/10/2026ABBVAbbVie Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$260.00 ➝ $280.007/9/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$249.00 ➝ $261.007/9/2026ABBVAbbVie JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $280.007/7/2026VRTXVertex Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$543.00 ➝ $570.007/6/2026ABBVAbbVie HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.17$15.14 per share16.38($1.83) per share-135.55VRTXVertex Pharmaceuticals$12.00B10.16$17.39 per share27.62$73.57 per share6.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03122.2015.470.815.79%-576.45%13.39%7/31/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8628.4825.322.0735.51%23.86%17.13%8/3/2026 (Estimated)Latest VRTX and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/3/2026Q2 2026VRTXVertex Pharmaceuticals$4.72N/AN/AN/A$3.22 billionN/A7/31/2026Q2 2026ABBVAbbVie$3.71N/AN/AN/A$16.78 billionN/A5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.79%+6.80%340.89%53 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest VRTX and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/18/2026ABBVAbbViequarterly$1.733.19%7/15/20267/15/20268/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableVRTX and ABBV HeadlinesRecent News About These CompaniesTeachers Retirement System of The State of Kentucky Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX1 hour ago | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Calamos Advisors LLC2 hours ago | marketbeat.comVertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for InvestorsJuly 13 at 11:42 PM | finance.yahoo.comVertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for InvestorsJuly 13 at 7:01 PM | zacks.comDoes Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?July 13 at 6:41 PM | fool.comVortex Energy Corp. Announces Closing of LIFE OfferingJuly 13 at 6:41 PM | finance.yahoo.comDoes Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?July 13 at 2:50 PM | fool.comWhat to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings ReportJuly 13 at 10:11 AM | barchart.comVertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology UpsideJuly 13 at 6:11 AM | tipranks.comLGT Fund Management Co Ltd. Takes $2.26 Million Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 13 at 5:36 AM | marketbeat.comFifth Third Bancorp Acquires 66,341 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 13 at 3:43 AM | marketbeat.comAMF Tjanstepension AB Has $139.73 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXJuly 13 at 3:12 AM | marketbeat.comCitizens Financial Group Inc. RI Purchases 6,421 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 12 at 11:19 AM | marketbeat.comVertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In CanadaJuly 11 at 11:41 PM | finance.yahoo.comVertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology PowerhouseJuly 11 at 5:01 PM | marketbeat.comManning & Napier Advisors LLC Has $98.50 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 11 at 10:39 AM | marketbeat.comCandriam S.C.A. Purchases 3,623 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 11 at 9:19 AM | marketbeat.comWhy This Pharmaceutical Stock Jumped Close to 100% This WeekJuly 10, 2026 | fool.comIs This Biotech Stock a Buy Near Its 52-Week High?July 10, 2026 | fool.comIf You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth NowJuly 10, 2026 | finance.yahoo.comThe Long Climb Back For Ionis StockJuly 10, 2026 | trefis.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026VRTX and ABBV Company DescriptionsAbbVie NYSE:ABBV$248.06 -0.02 (-0.01%) Closing price 07/13/2026 03:59 PM EasternExtended Trading$248.51 +0.45 (+0.18%) As of 06:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Vertex Pharmaceuticals NASDAQ:VRTX$480.25 -5.14 (-1.06%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$480.00 -0.25 (-0.05%) As of 06:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
